Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company specializing in medical devices for nerve repair. Their primary product, Remplir, is designed for connecting severed nerves, protecting damaged nerves, and capping nerve ends after amputation. The company is focused on expanding its market presence in the US, EU, and UK, targeting a total addressable market exceeding US$3.5 billion.
Average Trading Volume: 591,386
Technical Sentiment Signal: Buy
Current Market Cap: A$278.3M
See more data about OCC stock on TipRanks’ Stock Analysis page.